Design Therapeutics Stock Today
| DSGN Stock | USD 3.72 0.06 1.59% |
Performance13 of 100
| Odds Of DistressLess than 19
|
Design Therapeutics is selling at 3.72 as of the 29th of April 2024; that is -1.59% down since the beginning of the trading day. The stock's open price was 3.78. Design Therapeutics has less than a 19 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for Design Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of March 2024 and ending today, the 29th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of March 2021 | Category Healthcare | Classification Health Care |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. The company has 56.49 M outstanding shares of which 2.39 M shares are currently shorted by private and institutional investors with about 6.07 trading days to cover. More on Design Therapeutics
Moving against Design Stock
| 0.83 | ETON | Eton Pharmaceuticals Upward Rally | PairCorr |
| 0.78 | EVOK | Evoke Pharma | PairCorr |
| 0.65 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.62 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.44 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
| 0.43 | SBFMW | Sunshine Biopharma | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Design Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Design Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Design Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CoFounder | Pratik Shah | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Design Therapeutics report their recommendations after researching Design Therapeutics' financial statements, talking to executives and customers, or listening in on Design Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Design Therapeutics. The Design consensus assessment is calculated by taking the average forecast from all of the analysts covering Design Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Design Therapeutics' liquidity, profitability, solvency, and operating efficiency, Design Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Design Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Design Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Design Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Design Therapeutics' financial leverage. It provides some insight into what part of Design Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Design Therapeutics (DSGN) is traded on NASDAQ Exchange in USA. It is located in 6005 Hidden Valley Road, Carlsbad, CA, United States, 92011 and employs 58 people. Design Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 213.55 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Design Therapeutics's market, we take the total number of its shares issued and multiply it by Design Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Design Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 56.49 M outstanding shares of which 2.39 M shares are currently shorted by private and institutional investors with about 6.07 trading days to cover.
Design Therapeutics currently holds about 359.38 M in cash with (58.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Design Therapeutics Probability Of Bankruptcy
Ownership AllocationDesign Therapeutics holds a total of 56.49 Million outstanding shares. Over half of Design Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Design Therapeutics. Please watch out for any change in the institutional holdings of Design Therapeutics as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Design Ownership Details
Design Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Design Therapeutics jumping above the current price in 90 days from now is about 13.6%. The Design Therapeutics probability density function shows the probability of Design Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.2531 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Design Therapeutics will likely underperform. Additionally, design Therapeutics has an alpha of 0.6523, implying that it can generate a 0.65 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Design Therapeutics to move above the current price in 90 days from now is about 13.6 (This Design Therapeutics probability density function shows the probability of Design Stock to fall within a particular range of prices over 90 days) .
Design Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Design Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Design Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Design Therapeutics' value.| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2023-12-31 | 662.7 K | |
| Renaissance Technologies Corp | 2023-12-31 | 648.8 K | |
| Two Sigma Advisers, Llc | 2023-12-31 | 585 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 543.5 K | |
| Two Sigma Investments Llc | 2023-12-31 | 428.2 K | |
| Millennium Management Llc | 2023-12-31 | 420.1 K | |
| Northern Trust Corp | 2023-12-31 | 372.9 K | |
| Walleye Trading Advisors, Llc | 2023-12-31 | 362.4 K | |
| Assenagon Asset Management Sa | 2024-03-31 | 347.8 K | |
| Sr One Capital Management, Lp | 2023-12-31 | 6.5 M | |
| Logos Global Management Lp | 2023-12-31 | 5 M |
Design Therapeutics Historical Income Statement
Design Therapeutics Income Statement is one of the three primary financial statements used for reporting Design's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Design Therapeutics revenue and expense. Design Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Design Therapeutics' Depreciation And Amortization is very stable compared to the past year. As of the 29th of April 2024, Interest Expense is likely to grow to about 5.7 M, while Selling General Administrative is likely to drop about 12 M. View More FundamentalsDesign Stock Against Markets
Picking the right benchmark for Design Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Design Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Design Therapeutics is critical whether you are bullish or bearish towards Design Therapeutics at a given time. Please also check how Design Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Design Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Design Therapeutics Corporate Management
Elected by the shareholders, the Design Therapeutics' board of directors comprises two types of representatives: Design Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Design. The board's role is to monitor Design Therapeutics' management team and ensure that shareholders' interests are well served. Design Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Design Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aseem Ansari | CoFounder Advisor | Profile | |
| Sean Jeffries | Chief Officer | Profile | |
| Elizabeth Gordon | Senior Affairs | Profile | |
| Joo MD | CEO Pres | Profile | |
| MD FACC | Chief Officer | Profile | |
| Dawn Giangiulio | Controller | Profile |
How to buy Design Stock?
Before investing in Design Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Design Therapeutics. To buy Design Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Design Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Design Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Design Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Design Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Design Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Design Stock please use our How to Invest in Design Therapeutics guide.
Already Invested in Design Therapeutics?
The danger of trading Design Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Design Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Design Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Design Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Design Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Design Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Design Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Design Therapeutics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.Note that the Design Therapeutics information on this page should be used as a complementary analysis to other Design Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Design Stock analysis
When running Design Therapeutics' price analysis, check to measure Design Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Design Therapeutics is operating at the current time. Most of Design Therapeutics' value examination focuses on studying past and present price action to predict the probability of Design Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Design Therapeutics' price. Additionally, you may evaluate how the addition of Design Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Design Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Revenue Per Share 0.001 | Return On Assets (0.15) | Return On Equity (0.22) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.